A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer

C Qvortrup, B V Jensen, T Fokstuen, S E Nielsen, N Keldsen, B Glimelius, B Bjerregaard, J Mejer, F O Larsen, P Pfeiffer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2009-Jul-21
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind21
Udgave nummer1
Sider (fra-til)87-91
ISSN0923-7534
DOI
StatusUdgivet - 21. jul. 2009

Fingeraftryk

oxaliplatin
Colorectal Neoplasms
Disease-Free Survival
Capecitabine

Citer dette

@article{5af69a20d7a511deb0fe000ea68e967b,
title = "A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer",
abstract = "BACKGROUND: Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity. PATIENTS AND METHODS: One hundred and forty-one patients with unresectable mCRC were enrolled in a randomized study comparing standard XELOX (XELOX(30)), arm A, and XELOX(30Chron), arm B-both with short-time infusion of oxaliplatin-with the primary aim of reducing overall toxicity. RESULTS: Overall toxicity grade 2-4 was 90{\%} versus 85{\%}, P = 0.47 and grade 3-4 was 31{\%} versus 37{\%}, P = 0.6 in arm A and B, respectively. We found no significant differences in median overall survival (17.6 versus 15.5 months; P = 0.068) and median progression-free survival (8.9 versus 8.8 months; P = 0.7). The incidence of grade 3 neuropathy was 16{\%} in arm A and 19{\%} in arm B (P = 0.7) after a cumulative dose of oxaliplatin of 1000 mg/m(2). CONCLUSION: XELOX(30Chron) does not reduce toxicity or improve efficacy. A 30-min infusion of oxaliplatin is safe and does not increase the severity of chronic neuropathy.",
author = "C Qvortrup and Jensen, {B V} and T Fokstuen and Nielsen, {S E} and N Keldsen and B Glimelius and B Bjerregaard and J Mejer and Larsen, {F O} and P Pfeiffer",
year = "2009",
month = "7",
day = "21",
doi = "10.1093/annonc/mdp272",
language = "English",
volume = "21",
pages = "87--91",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Heinemann",
number = "1",

}

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer. / Qvortrup, C; Jensen, B V; Fokstuen, T; Nielsen, S E; Keldsen, N; Glimelius, B; Bjerregaard, B; Mejer, J; Larsen, F O; Pfeiffer, P.

I: Annals of Oncology, Bind 21, Nr. 1, 21.07.2009, s. 87-91.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer

AU - Qvortrup, C

AU - Jensen, B V

AU - Fokstuen, T

AU - Nielsen, S E

AU - Keldsen, N

AU - Glimelius, B

AU - Bjerregaard, B

AU - Mejer, J

AU - Larsen, F O

AU - Pfeiffer, P

PY - 2009/7/21

Y1 - 2009/7/21

N2 - BACKGROUND: Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity. PATIENTS AND METHODS: One hundred and forty-one patients with unresectable mCRC were enrolled in a randomized study comparing standard XELOX (XELOX(30)), arm A, and XELOX(30Chron), arm B-both with short-time infusion of oxaliplatin-with the primary aim of reducing overall toxicity. RESULTS: Overall toxicity grade 2-4 was 90% versus 85%, P = 0.47 and grade 3-4 was 31% versus 37%, P = 0.6 in arm A and B, respectively. We found no significant differences in median overall survival (17.6 versus 15.5 months; P = 0.068) and median progression-free survival (8.9 versus 8.8 months; P = 0.7). The incidence of grade 3 neuropathy was 16% in arm A and 19% in arm B (P = 0.7) after a cumulative dose of oxaliplatin of 1000 mg/m(2). CONCLUSION: XELOX(30Chron) does not reduce toxicity or improve efficacy. A 30-min infusion of oxaliplatin is safe and does not increase the severity of chronic neuropathy.

AB - BACKGROUND: Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity. PATIENTS AND METHODS: One hundred and forty-one patients with unresectable mCRC were enrolled in a randomized study comparing standard XELOX (XELOX(30)), arm A, and XELOX(30Chron), arm B-both with short-time infusion of oxaliplatin-with the primary aim of reducing overall toxicity. RESULTS: Overall toxicity grade 2-4 was 90% versus 85%, P = 0.47 and grade 3-4 was 31% versus 37%, P = 0.6 in arm A and B, respectively. We found no significant differences in median overall survival (17.6 versus 15.5 months; P = 0.068) and median progression-free survival (8.9 versus 8.8 months; P = 0.7). The incidence of grade 3 neuropathy was 16% in arm A and 19% in arm B (P = 0.7) after a cumulative dose of oxaliplatin of 1000 mg/m(2). CONCLUSION: XELOX(30Chron) does not reduce toxicity or improve efficacy. A 30-min infusion of oxaliplatin is safe and does not increase the severity of chronic neuropathy.

U2 - 10.1093/annonc/mdp272

DO - 10.1093/annonc/mdp272

M3 - Journal article

VL - 21

SP - 87

EP - 91

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -